Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 193 full-time employees. The company went IPO on 2021-07-22. The firm combines AI with scalable wet lab technologies to create biologics for patients. The company has built an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The firm uses its platform to predict, identify, design, construct, screen, select and scale production of biologic drug candidates for its partners, and learn from the data it generates. Its SoluPro technology is a multiplex synthetic biology approach that overcomes the limitations of highest-throughput automation labs. The firm supports its generative AI designs with its wet lab's high-throughput functional validation capabilities. The firm applies generative AI to design optimal drug candidates based on target affinity, safety, manufacturability, and other traits.